A novel KIF5B-ALK variant in nonsmall cell lung cancer

Cancer

Volumn 117, Issue 12, 2011, Pages 2709-2718

  Wong, Daisy Wing Sze ^a   Leung, Elaine Lai Han ^a   Wong, Sunny Kit Man ^a   Tin, Vicky Pui Chi ^a   Sihoe, Alan Dart Loon ^b   Cheng, Lik Cheung ^b   Au, Joseph Siu Kie ^c   Chung, Lap Ping ^a   Wong, Maria Pik ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

EML4 ALK; fusion gene; KIF5B ALK; nonsmall cell lung cancer; oncogenesis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; COMPLEMENTARY DNA; GENOMIC DNA; KINESIN 5; MICROTUBULE ASSOCIATED PROTEIN 4; PROTEIN KINASE B; STAT3 PROTEIN;

5' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER PATIENT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EML4 ALK GENE; ENZYME ACTIVATION; EXON; FUSION GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIF5B ALK GENE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELL PROLIFERATION; GENETIC VARIATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KINESIN; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 79955973559     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25843     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ., Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66. (Pubitemid 46148091)
2. Sato M, Shames DS, Gazdar AF, Minna JD., A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007; 2: 327-343. (Pubitemid 47181718)
3. Aplan PD., Causes of oncogenic chromosomal translocation. Trends Genet. 2006; 22: 46-55. (Pubitemid 43011997)
4. Mitelman F, Johansson B, Mertens F., The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007; 7: 233-245. (Pubitemid 46480968)
5. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644-648. (Pubitemid 41528150)
6. Kaye FJ., Mutation-associated fusion cancer genes in solid tumors. Mol Cancer Ther. 2009; 8: 1399-1408.
7. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM., Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol Med. 2006; 12: 529-536. (Pubitemid 44633807)
8. Prensner JR, Chinnaiyan AM., Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev. 2009; 19: 82-91.
9. Chen W, Kalscheuer V, Tzschach A, et al. Mapping translocation breakpoints by next-generation sequencing. Genome Res. 2008; 18: 1143-1149. (Pubitemid 351931165)
10. Fullwood MJ, Wei CL, Liu ET, Ruan Y., Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res. 2009; 19: 521-532.
11. Ruan Y, Ooi HS, Choo SW, et al. Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using paired-end tags (PETs). Genome Res. 2007; 17: 828-838. (Pubitemid 46919718)
12. Campbell PJ, Stephens PJ, Pleasance ED, et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet. 2008; 40: 722-729. (Pubitemid 351748860)
13. Mano H., Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008; 99: 2349-2355.
14. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G., The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008; 8: 11-23.
15. Li R, Morris SW., Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev. 2008; 28: 372-412. (Pubitemid 351590540)
16. Palmer RH, Vernersson E, Grabbe C, Hallberg B., Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009; 420: 345-361.
17. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131: 1190-1203. (Pubitemid 350235027)
18. Shinmura K, Kageyama S, Tao H, et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer. 2008; 61: 163-169.
19. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009; 15: 3143-3149.
20. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006; 12: 1647-1653.
21. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009; 115: 1723-1733.
22. Niclas J, Navone F, Hom-Booher N, Vale RD., Cloning and localization of a conventional kinesin motor expressed exclusively in neurons. Neuron. 1994; 12: 1059-1072. (Pubitemid 24178198)
23. Amin HM, Lai R., Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007; 110: 2259-2267. (Pubitemid 47523143)
24. Pulford K, Morris SW, Turturro F., Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol. 2004; 199: 330-358. (Pubitemid 38580430)
25. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14: 4275-4283.
26. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005; 11: 623-629. (Pubitemid 40868302)
27. Zhang Q, Raghunath PN, Xue L, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002; 168: 466-474. (Pubitemid 34014150)
28. Armstrong F, Duplantier MM, Trempat P, et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene. 2004; 23: 6071-6082. (Pubitemid 39178860)
29. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.